Antisense oligonucleotide drug design

Current Pharmaceutical Design

Volumn 10, Issue 7, 2004, Pages 769-784

  Schiavone, Nicola ^a   Donnini, M ^a   Nicolin, A ^b   Capaccioli, Sergio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Antisense oligonucleotides; Cancer; Drug; Gene expression; Gene function; Gene therapy; Human diseases; Posttranscriptional control; Ribozymes; RNA; RNA interference; Therapeutics

Indexed keywords

ADENOVIRUS VECTOR; ALPHA GLOBULIN; ANTISENSE OLIGONUCLEOTIDE; BETA ACTIN; CARBOPLATIN; COMPLEMENTARY DNA; COMPLEMENTARY RNA; CYCLIC AMP DEPENDENT PROTEIN KINASE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOMIVIRSEN; GENE EXPRESSION MODULATOR 231; ISIS 3521; MESSENGER RNA; METHYLPHOSPHONIC ACID; MICROSPHERE; MORPHOLINE DERIVATIVE; OBLIMERSEN; PACLITAXEL; POLYETHYLENE; POLYGLACTIN; POLYMER; PORPHYRIN DERIVATIVE; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN MDM2; PROTEIN P53; RAS PROTEIN; RIBONUCLEASE; RIBOZYME; UNINDEXED DRUG;

ADENO ASSOCIATED VIRUS; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVITY; FATIGUE; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENETIC ANALYSIS; GENETIC TRANSCRIPTION; GENOTOXICITY; HUMAN; KNOCKOUT GENE; LUNG NON SMALL CELL CANCER; MEDICAL GENETICS; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; RNA TRANSLATION; SEVERE ACUTE RESPIRATORY SYNDROME; THROMBOCYTOPENIA; TRANSPOSON; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; GENE EXPRESSION; HUMANS; INFORMATION THEORY; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 1442276553     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043452956     Document Type: Review

References (159)

1. Paterson BM, Roberts BE, Kuff EL. Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc Natl Acad Sci USA 1977; 74: 4370-4.
2. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodoxynucleotide. Proc Natl Acad Sci USA 1978; 75: 280-4
3. Mattick JS. Non-coding RNAs: the architets of eukaryotic complexity. EMBO Rep 2001; 2: 986-991.
4. Pestka S, Daugherty BL, Jung V, Hotta K, Pestka RK. Anti-mRNA: specific inhibition of translation of single mRNA molecules. Proc Natl Acad Sci USA 1984; 81: 7525-8.
5. Casey BP, Glazer PM. Gene targeting via triple-helix formation. Prog Nucleic Acid Res Mol Biol 2001; 67: 163-92.
6. Mercatante DR, Kole R. Control of Alternative Splicing by antisense oligonucleotides as a potential chemotherapy: effects on gene expression. Biochim Biophys Acta 2002; 1587: 126-32.
7. Thommes P, Hubscher U. Eukaryotic DNA replication. Enzymes and proteins acting at the fork. Eur J Biochem 1990; 194: 699-712.
8. Doherty EA, Doudna JA. Ribozyme structures and mechanisms. Annu Rev Biophys Biomol Struct 2001; 30: 457-75.
9. Kiss T, Marshallsay C, Filipowicz W. 7-2/MRP RNAs in plant and mammalian cells: association with higher order structures in the nucleolus. EMBO J 1992; 11: 3737-46.
10. Epstein LM, Gall JG. Self-cleaving transcripts of satellite DNA from the newt. Cell 1987; 48: 535-43.
11. Saville BJ, Collins RA. A site-specific self-cleavage reaction performed by a novel RNA in Neurospora mitochondria. Cell 1990; 61: 685-96.
12. Forster AC, Altman S. Similar cage-shaped structures for the RNA components of all ribonuclcase P and ribonuclease MRP enzymes. Cell 1990; 62: 407-9.
13. Kruger K, Grabowski PJ, Zaug AJ, Sands J, Gottschling DE, Cech TR. Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell 1982; 31: 147-7.
14. Taylor JM. Hepatitis delta virus: cis and trans functions required for replication. Cell 1990; 61: 371-3.
15. Luzi E, Papucci L, Schiavone N, Donnini M, Lapucci A, Tempestini A, et al. Downregulation of bcl-2 expression in lymphoma cells by bcl-2 ARE-targeted modified, synthetic ribozyme. Cancer Gene Ther 2003; 10: 201-8.
16. Brody EN, Gold, L. Aptamers as therapeutic and diagnostic agents. J Biotechnol 2000; 74: 5-13.
17. Breaker RR. Catalytic DNA: in training and seeking employment. Nature Biotechnology 1999; 17: 422-3
18. Breaker RR. Tech. Sight. Molecular biology. Making catalytic DNAs. Science 2000: 290: 2095-6.
19. Akhtar S, Hughes MD, Khan A, Bibby M, Hussain M, Nawaz Q, et al. The delivery of antisense therapeu3tics. Adv Drug Deliv Rev 2000; 44: 3-21.
20. Eder PS, DeVine RJ, Dagle IM, Walder JA. Substrate specificity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Antisense Res Dev 1991; 1: 141-51.
21. Crooke RM, Graham MJ, Martin MJ, Lemonidis KM, Wyrzykiewiecz T, Cnmmins LL. Metabolism of antisense oligonucleotides in rat liver homogenates. J Pharmacol Exp Ther 2000; 292: 140-149.
22. Ho PT, Ishiguro K, Wickstrom E, Sartorelli AC. Non-sequence-specific inhibition of transferrin receptor expression in HL-60 leukemia cells by phosphorothioate. Antisense Res Dev 1991; 1: 329-42.
23. Wilckstrom E. Oligodeoxynucleotides stability in subcellular extracts and culture media. J Biochem Biophys Methods 1996; 13: 97-107.
24. Akhtar S, Kole R, Juliano RL. Stability of antisense DNA oligonucleotide analogs in cellular extracts and sera. Life Sci 1991; 49: 1793-801.
25. Hudson AJ, Normand N, Ackroyd J, Aktar S. Cellular delivery of hammerhead ribozymes conjugated to a transferrin receptor antibody. Int J Pharmacol 1999; 182: 49-58
26. Ion G. Oligonucleotide analogs as potential chemotherapeutic agent. Pharmaceutical Research 1988; 5: 539-49.
27. Leumann CJ. DNA analogues: from supramolecular principles to biological properties. Bioor Med Chem 2002; 10: 841-54.
28. Egli M, Gryaznov SM. Synthetic oligonucleotides as RNA mimetics: 2′-modified Rnas and N3′→P5′ phosphoramidates. Cell Mol Life Sci 2000; 57: 1440-56.
29. Agrawal S, Goodchild J, Civeira MP, Thornton AH, Sarin PS, Zamecnik PC. Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus. Proc Natl Acad Sci USA 1988; 85: 7079-83.
30. Crooke ST. Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta 1999; 1489: 31-44.
31. Goodchild J. Conjugates of oligonucleotides and modified oligonucleotides: a review of their synthesis and properties. Bioconjug Chem 1990; 1: 167-87
32. Cook PD, Crooke ST, Lebleu B. Antisense research and applications CRC Press, Boca Raton FL, 1993.
33. Stec WJ, Zon G, Egan W, Stec B. Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogues of oligodexyribonucleotides. J Am Chem Soc 1984; 106: 6077-80.
34. Thaler DS, Liu S, Tombline G. Extending the chemistry that supports genetic information transfer in vivo: phosphorothioate DNA, phosphorothioate RNA, 2′-O-methyl RNA, and methylphosphonate DNA. Proc Natl Acad Sci USA 1996; 93: 1352-6.
35. Inoue H, Hayase Y, Imura A, Iwau S, Miura K, Ohtsuka E. Synthesis and hybridization studies on two complementary nona(2′-O-methyl)ribonucleotides. Nucleic Acids Res 1987; 15: 6131-48.
36. Sproat BS, Lamond AI, Beijer B, Neuner P, Ryder U. Highly efficient chemical synthesis of 2′-O-methyloligoribonucleotides and tetrabiotinylated derivatives; novel probes that are resistant to degradation by RNA or DNA specific nucleases. Nucleic Acids Res 1989; 17: 3373-86.
37. Wahlestedt C, Salmi P, Good L, Kela J, Johnsson T, Hokfelt T, et al. Proc Natl Acad Sci USA 2000; 97: 5633-8.
38. Summerton J. Morpholino antisense oligomers: the case for an Rnase H-independent structural type. Biochim Biophys Acta 1999; 1489: 141-58.
39. Heasman J. Morpholino oligos: making sense of antisense? Dev Biol 2002; 243: 209-14.
40. Garcia-Chaumont C, Seksek O, Grzybowska J, Borowski E, Bolard J. Delivery systems for antisense oligonucleotides. Pharmacol Ther 2000; 87: 255-77.
41. Capaccioli S, Di Pasquale G, Mini E, Mazzei T, Quattrone A. Cationic lipids improve antisense oligonucleotide uptake and prevent degradation in cultured cells and in human serum. Biochem Biophys Res Commun 1993; 197: 818-25.
42. Zelphati O, Szoka FC Jr. Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharm Res 1996; 13: 1367-72.
43. Williams SA, Chang L, Buzby JS, Suen Y, Cairo MS. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth. Leukemia 1996; 10: 1980-9.
44. Manorharan M. Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery and mechanism of action. Antisense Nucleic Acid Drug Dev 2002; 12: 103-28.
45. Dass CR. Cytotoxicity issues pertinent to lipoplex-mediated gene therapy in-vivo. J Pharm Pharmacol 2002; 54: 593-601.
46. Benimetskaya L, Takle GB, Vilenchik M, Lebedeva I, Miller P, Stein CA. Cationic porphyrins: novel delivery vehicles for antisense oligodeoxynucleotides. Nucleic Acids Res 1998; 26: 5310-7.
47. Kralova J, Dvorak M, Kral V. Novel cationic transport agents for oligonucleotide delivery into primary leukemic cells. J Med Chem 2003; 46: 2049-56.
48. Bielinska A, Kukowska-Latallo JF, Johnson J, Tomalia DA, Baker JR Jr. Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res 1996; 24: 2176-82.
49. Sato N, Kobayashi H, Saga T, Nakamoto Y, Ishimori T, Togashi K, et al. Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. Clin Cancer Res 2001; 7: 3606-12.
50. Vorobjev PE, Zarytova VF, Bonora GM. Oligonucleotide conjugated to linear and branched high molecular weight polyethylene glycol as substrates for RNase H. Nucleosides Nucleotides 1999; 18: 2745-50.
51. Dheur S, Dias N, van Aerschot A, Herdewijn P, Bettinger T, Remy JS, et al. Polyethylenimine but not cationic lipid improves antisense activity of 3′-capped phosphodiester oligonucleotides. Antisense Nucleic Acid Drug Dev 1999; 9: 515-25.
52. De Rosa G, Bochot A, Quaglia F, Besnard M, Fattal E. A new delivery system for antisense therapy: PLGA microspheres encapsulating oligonucleotide/polyethyleneimine solid complexes. Int J Pharm 2003; 254: 89-93.
53. Chavany C, Le Doan T, Couvreur P, Puisieux F, Hélène C. Polyalkylcyanoacrylate nanoparticles as polymeric carriers for antisense oligonucleotides. Pharm Res 1992; 9: 441-9.
54. Plank C, Scherer F, Schillinger U, Bergemann C, Anton MJ. Magnetofection: enhancing and targeting gene delivery with superparamagnetic nanoparticles and magnetic fields. Liposome Res 2003; 13: 29-32.
55. Krotz F, Wit C, Sohn HY, Zahler S, Gloe T, Pohl U, et al. Magnetofection-A highly efficient tool for antisense oligonucleotide delivery in vitro and in vivo. Mol Ther 2003; 7: 700-10.
56. Garbesi A, Bonazzi S, Zanella S, Capobianco ML, Giannini G, Arcamone F. Synthesis and binding properties of conjugates between oligodeoxynucleotides and daunorubicin derivatives. Nucleic Acids Res 1997; 25: 2121-8.
57. Gygi SP, Rochon Y, Franza BR, Aebersold R. Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 1999; 19: 1720-30.
58. Griffin TJ, Gygi SP, Ideker T, Rist B, Eng J, Hood L, et al. Complementary profiling of gene expression at the transcriptome and proteome levels in Saccharomyces cerevisiae. Mol Cell Proteomics 2002; 1: 323-33.
59. Quattrone A, Papucci L, Morganti L, Coronnello M, Mini E, Mazzei T, et al. Inhibition of MDR1 gene expression by antimessenger oligonucleotides lowers multiple drug resistance in neoplastic cells. Oncol Res 1994; 6: 311-20.
60. Vaish NK, Kore AR, Eckstein F. Recent developments in the hammerhead ribozyme field. Nucleic Acids Res 1998; 26: 5237-42.
61. Mlotshwa S, Voinnet O, Mette MF, Matzke M, Vaucheret H, Ding SW, et al. RNA silencing and the mobile silencing signal. Plant Cell 2002, 14 Suppl, S289.
62. Klinman DM. Therapeutic applications of CpG-containing oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev 1998; 8: 181-4.
63. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1999; 374: 546-9.
64. Krieg AM. From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA. Antisense Nucleic Acid Drug Dev 2001; 11: 181-8.
65. Krieg AM. The role of CpG motifs in innate immunity. Curr Opin Immunol 2000; 12: 35-43.
66. Lenert P, Stunz L, Yi AK, Krieg AM, Ashman RF. CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation. Antisense Nucleic Acid Drug Dev 2001; 11; 247-56.
67. Yi AK, Yoon JG, Hong SC, Redford TW, Krieg AM. Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-alpha production through activation of NF-kappaB. Int Immunol 2001; 13: 1391-1404.
68. Branch AD. A good antisense molecule is hard to find. Trends Biochem Sci 1998; 23: 45-50.
69. Hermann T, Patel DJ. Adaptive recognition by nucleic acid aptamers. Science 2000; 28: 820-5.
70. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-11.
71. Lee S, Elenbaas B, Levine AJ, Griffith J, Lee S, Elenbaas B. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the from of insertion/deletion mismatches. Cell 1995; 81: 1013-20.
72. Zotchev S, Protopopova M, Selivanova G. p53 C-terminal interaction with DNA ends and gaps has opposing effect on specific DNA binding by the core. Nucl Acids Res 2000; 28: 4005-12.
73. Tishler RB, Stuart KC, Coleman CN, Price BD. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 1993; 53: 2212-6.
74. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999; 59: 1391-9.
75. Siegel J, Fritsche M, Mai S, Brandner G, Ralf DH. Enhanced p53 activity and accumulation in response to DNA damage upon DNA transfection. Oncogene 1995; 11: 1363-70.
76. Huang LC, Clarkin KC, Wahl GM. Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc Natl Acad Sci USA 1996; 93: 4827-32.
77. Bakalkin G, Selivanova G, Yakovleva T, Kiseleva E, Kashuba E, Magnusson KP, et al. p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain. Nucleic Acids Res 1995; 23: 362-9.
78. Bakalkin G, Yakovleva T, Selivanova G, Magnusson KP, Szekely L, Kiseleva et al. p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc Natl Acad Sci USA 1994; 91: 413-7.
79. Jayaraman J, Prives C. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell 1995; 81: 1021-9.
80. Selivanova G, Iotsova V, Kiseleva E, Strom M, Bakalkin G, Grafstrom RC, et al. The single-stranded DNA end binding site of p53 coincides with the C-terminal regulatory region. Nucleic Acids Res 1996; 24: 3560-7.
81. Schiavone N, Papucci L, Luciani P, Lapucci A, Donnini M, Capaccioli S. Induction of apoptosis and mitosis inhibition by degraded DNA lipotransfection mimicking genotoxic drug effects. Biochem Biophys Res Commun 2000; 270: 406-14.
82. Papucci L, Schiavone N, Donnini M, Lapucci A, Luzi E, Tempestini A, et al. Phosphodiester oligonucleotides inhibit mitosis and trigger apoptosis by a non-antisense, p53-mediated mechanism. Antisense Nucleic Acid Drug Dev 2002; 12: 21-31.
83. Lebedeva I, Stein CA. Antisense Oligonucleotides: Promise and Reality. Annu Rev Pharmacol Toxicol 2001; 41: 403-19.
84. Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 2000; 356: 1728-33.
85. Mourelatos Z, Dostie J, Paushkin S, Sharma A, Charroux B, Abel L, et al. miRNPs: a novel class of ribonucleoproteins containing numerous microRNAs. Gene Dev 2002; 16: 720-8.
86. Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000; 404; 293-6.
87. Paddison PJ, Caudy AA, Hannon GJ. Stable suppression of gene expression by RNAi in mammalian cells. Proc Natl Acad Sci USA 2002; 99: 1443-8.
88. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67: 227-64.
89. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411: 494-8.
90. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001; 409: 363-6.
91. Knight SW, Bass B. A role for the RNase III enzyme DCR-1 in RNA interference and germ line development in Caenorhabditis Elegans. Science 2001; 293: 2269-71.
92. Ketting RF, Fisher SE, Bernstein E, Sijen T, Hannon GJ, Plasterk RH. A role for the RNase III enzyme DCR-1 in RNA interference and germ line development in Caenorhabditis Elegans. Genes Dev 2001; 15: 2654-9.
93. Hamada M, Ohtsuka T, Kawaida R, Koizumi M, Morita K, Furukawa H, et al. Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3′-ends of siRNAs. Antisense Nucleic Acid Drug Dev 2002; 12: 301-9.
94. Chiu YL, Rana TM. RNAi in human cells: basic structural and functional features of small interfering RNA. Mol Cell 2002; 10: 549-61.
95. Martinez J, Patkaniowska A, Urlaub H, Luhrmann R, Tuschl T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002; 110: 563-74.
96. Amarzguioui M, Holen T, Babaie E, Prydz H. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res 2003; 31: 589-95.
97. Ambros V. microRNAs: tiny regulators with great potential. Cell 2001; 107: 823-6.
98. Banerjee D, Slack F. Control of developmental timing by small temporal RNAs: a paradigm for RNA-mediated regulation of gene expression. BioEssays 2002; 24: 119-29.
99. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002; 16: 948-58.
100. Doench JG, Petersen CP, Sharp PA. siRNAs can function as miRNAs. Genes Dev 2003; 17; 438-42.
101. Yang D, Buchholz F, Huang Z, Goga A, Chen CY, Brodsky, et al. Short RNA duplexes produced by hydrolysis with Escherichia coli RNase III mediate effective RNA interference in mammalian cells. Proc Natl Acad Sci USA 2002; 99: 9942-7.
102. Bohula EA, Salisbury AJ, Sohail M, Playford MP, Riedemann J, Southern EM, et al. The Efficacy of Small Interfering RNAs Targeted to the Type 1 Insulin-like Growth Factor Receptor (IGF1R) Is Influenced by Secondary Structure in the IGF1R Transcript. J Biol Chem 2003; 278: 15991-7.
103. Vickers TA, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF. Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J Biol Chem 2003; 278: 7108-18.
104. Miyagishi M, Hayashi M, Taira K. Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev 2003; 13: 1-7.
105. Aoki Y, Cioca DP, Oidaira H, Kamiya J, Kiyosawa K. RNA interference may be more potent than antisense RNA in human cancer cell lines. Clin Exp Pharmacol Physiol 2003; 30: 96-102.
106. Hemmings-Mieszczak M, Dorn G, Natt FJ, Hall J, Wishart WL. Independent combinatorial effect of antisense oligonucleotides and RNAi-mediated specific inhibition of the recombinant Rat P2X(3) receptor. Nucleic Acids Res 2003; 31: 2117-26.
107. Yelin R, Dahary D, Sorek R, Levanon EY, Goldstein O, Shoshan A, et al. Widespread occurrence of antisense transcription in the human genome. Nat Biotechnol 2003; 21: 379-85.
108. Patzel V, Steidl U, Kronenwett R, Haas R, Sczakiel G. A theoretical approach to select effective antisense molecule oligodeoxyribonucleotides at high statistic probability. Nucleic Acids Research 1999; 27: 4328-34.
109. Ho SP, Britton DH, Stone BA, Behrens DL, Leffet LM, Hobbs FW, et al. Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotides library. Nucleic Acids Res 1996; 24: 1901-07.
110. Milner N, Mir KU, Southern EM. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat Biotechnol 1997; 15: 537-41.
111. Lieber A, Strauss M. Selection of efficient cleavage sites in target RNAs by using ribozyme expression library. Mol Cell Biol 1995; 15: 540-51.
112. Anderson P, Monforte J, Tritz R, Nesbitt S, Hearst J, Hampel A. Mutagenesis of the hairpin ribozyme. Nucleic Acids Res 1994; 22: 1096-100.
113. Wang DY, Lai BH, Feldman AR, Sen D. A general approach for the use of oligonucleotide effectors to regulate the catalysis of RNA-cleaving ribozymes and DNAzymes. Nucleic Acids Research 2002; 30: 1735-42.
114. Matveeva OV, Tsodikov AD, Giddings M, Freier SM, Wyatt JR, Spiridonov AN, et al. Identification of sequence motif in oligonucleotides whose precence is correlated with antisense activity. Nucleic Acid Research 2000; 28: 2862-5.
115. Sohail M, Hochegger H, Klotzbucher A, Guellec RL, Hunt T, Southern EM. Antisense oligonucleotides selected by hybridisation scanning arrays are effective reagents in vivo. Nucleic Acids Res 2001; 29: 2041-51.
116. Scherr M, Rossi JJ, Sczakiel G, Patzel V. RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts. Nucleic Acids Res 2000; 28: 2455-61.
117. Sohail M, Southern EM. Selecting optimal antisense reagents. Adv Drug Deliv Rev, 2000; 44: 23-34.
118. Lloyd BH, Giles RV, Spiller DG, Grzybowski J, Tidd DM, Sibson DR. Determination of optimal sites of antisense oligonucleotides cleavage within TNF-α mRNA. Nucleic Acids Research 2001; 29: 3664-73.
119. Allawi HT. Mapping of RNA accessible sites by extension of random oligonucleotide libraries with reverse transcriptase. RNA 2001; 7: 314-27.
120. Jain KK. Cambridge Healthtech Institute's Third Annual Conference on Lab-on-a-Chip and Microarrays. 22-24 January 2001, Zurich, Switzerland. Pharmacogenomics 2001; 2: 73-7.
121. Kennewell, P. Technology evaluation: ISIS-104838, OraSense. Curr Opin Mol Ther 2003; 5: 76-80.
122. Zinker BA, Rondinone CM, Trevillyan JM, Gum RJ, Clampit JE, Waring JF, et al. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci USA 2002; 99: 11357-62.
123. Jansen, B, Zangemeister-Wittke, U. Antisense therapy for cancer - the time of truth Lancet Oncol 2002; 3: 672-83.
124. Gleave M, Miyake H, Zangemeister-Wittke U, Jansen B. Antisense therapy: current status in prostate cancer and other malignancies. Cancer Metastasis Rev 2002; 21: 79-92.
125. Holmlund JT, Monia BP, Kwoh TJ, Dorr FA. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development. Curr Opin Mol Ther 1999; 1: 372-85.
126. Mercola D, Cohen JS. Antisense approaches to cancer gene therapy. Cancer Gene Ther 1995; 2: 47-59.
127. Tseng BY, Brown KD. Antisense oligonucleotide technology in the development of cancer therapeutics. Cancer Gene Ther 1994; 1: 65-71.
128. Carter G, Lemoine NR. Antisense technology for cancer therapy: does it make sense? Br J Cancer 1993; 67: 869-76.
129. Field AK. Oligonucleotides as inhibitors of human immunodeficiency virus. Curr Opin Mol Ther 1999; 1: 323-31.
130. Erikson JM, Freeman GL, Chandrasekar B. Ultrasound-targeted antisense oligonucleotide attenuates ischemia/reperfusion-induced myocardial tumor necrosis factor-alpha J Mol Cell Cardiol 2003; 35: 119-30.
131. Phillips MI. Gene therapy for hypertension: the preclinical data. Hypertension 2001; 8: 543-8.
132. Tsuboi R, Ueki R, Ogawa H. Third intercontinental meeting of hair research societies, June 13-15 2001, Tokyo, Japan (Abstract 075)
133. Davis AJ, Gelmon KA, Siu LL, Moore MJ, Britten CD, Mistry N, et al. A phase I trial and pharmacokinetic (PK) study of the human DNA methyltransferase antisense oligodeoxyribonucleotide MG98 given as a 21 day continuous infusion every 4 weeks. Invest New Drugs 2003; 21:85-97.
134. Green DW, Roh H, Pippin J, Drebin JA. Antisense oligonucleotides: an evolving technology for the modulation of gene expression in human disease. J Am Coll Surg 2000; 191: 93-105.
135. Morelli S, Delia D, Capaccioli S, Quattrone A, Schiavone N, Bevilacqua A, et al. The antisense bcl-2-IgH transcript is an optimal target for synthetic oligonucleotides. Proc Natl Acad Sci USA 1997; 94: 8150-5.
136. Chang EH, Miller PS, Cushman C, Devadas K, Pirollo KF, Ts'o PO, et al. Antisense inhibition of ras p21 expression that is sensitive to a point mutation. Biochemistry 1991; 30: 8283-6.
137. Adjei AA, Dy GK, Erlichman C, Reid JM, Sloan JA, Pitot HC, et al. A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer. Clin Cancer Res 2003; 9: 115-23.
138. Geiger T, Muller M, Dean NM, Fabbro D. Antitumour activity of a PKC-alpha antisense oligonucleotide in combination with standard chemiotherapeutic agents against various human tumours transplanted into nude mice. Anticancer Drug Design 1998; 13: 35-45.
139. Tamm I, Dorken B, Hartmann G. Antisense therapy in oncology: new hope for an old idea? Lancet 2001; 358: 489-97.
140. Bradbury AW, Carter DC, Miller WR, Cho-Chung YS, Clair T. Protein kinase A (PKA) regulatory protein expression in colorectal cancer and related mucosa. Br J Cancer 1994; 69: 738-42.
141. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, Pepe S, et al. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. J Natl Cancer Inst 1998; 90: 738-42.
142. Matthes E, Lehmann C. Telomerase protein rather than its RNA is the target of phosphorothioate-modified oligonucleotides. Nucleic Acids Res 1999; 27: 1152-8.
143. Wong SC, Yu H, Moochhala SM, So JB. Antisense telomerase induced cell growth inhibition, cell cycle arrest and telomerase activity down-regulation in gastric and colon cancer cells. Anticancer Res 2003; 23: 465-9.
144. Morganti M, Coronnello M, Caciagli B, Biondi C, Quattrone A, Capaccioli S, et al. Modulation of dihydrofolate reductase gene expression in methotrexate-resistant human leukemia CCRF-CEM/E cells by antisense oligonucleotides. Anticancer Drugs 2000; 11: 285-94.
145. Quattrone A, Fibbi G, Anichini E, Pucci M, Zamperini A, Capaccioli S, et al. Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression. Cancer Res 1995; 55: 90-5.
146. Schendel SL, Montal M, Reed JC. Bcl-2 family proteins as ion-channels. Cell Death Differ 1998; 5: 372-380.
147. Tsujimoto Y, Shimizu S. Bcl-2 family: life-or-death switch. FEBS Lett 2000; 466: 6-10.
148. Huang H, Cheville JC, Pan Y, Roche PC, Schmidt LJ, Tindall DJ. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem 2001; 276: 38830-6.
149. Bevilacqua A, Ceriani MC, Schiavone N, Nicolin A. BCL-2 regulation targeting the AU-rich domain. Nucleosides Nucleotides Nucleic Acids 2000; 19: 1273-9.
150. Tortora G, Caputo R, Damiano V, Bianco R, Chen J, Agrawal S, et al. A novel MDM2 anti-sense oligonucleotide has anti-tumor activity and potentiates cytotoxic drugs acting by different mechanisms in human colon cancer. Int J Cancer 2000; 88: 804-9.
151. Yelin R, Dahary D, Sorek R, Levanon EY, Goldstein O, Shoshan A, et al. Widespread occurrence of antisense transcription in the human genome Nat Biotechnol 2003; 21: 379-85.
152. Capaccioli S, Quattrone A, Schiavone N, Calastretti A, Copreni E, Bevilacqua A, et al. A bcl-2/IgH antisense transcript deregulates bcl-2 gene expression in human follicular lymphoma t(14;18) cell lines Oncogene 1996; 13: 105-15.
153. Tufarelli C, Stanley JA, Garrick D, Sharpe JA, Ayyub H, Wood WG, et al. Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease. Nat Genet 2003; 34: 157-65.
154. Gewirtz AM, Sokol DL, Ratajczak MZ. Nucleic acid therapeutics: state of the art and future prospects. Blood 1998; 92: 712-36.
155. O'Neil NJ, Martin RL, Tomlinson ML, Jones MR, Coulson A, Kuwabara PE. RNA-mediated interference as a tool for identifying drug targets. Am J Pharmacogenomics 2001; 1: 45-53.
156. Santoro SW, Joyce GF. A general purpose RNA-cleaving DNA enzyme. Proc Natl Acad Sci USA 1997; 94: 4262-6.
157. Alvarez D, Wiley RE, Jordana M. Cytokine therapeutics for asthma: an appraisal of current evidence and future prospects. Curr Pharm Design 2001; 7(11): 1059-81.
158. Haney SA, Alksne LE, Dunman PM, Murphy E, Projan SJ. Genomics in anti-infective drug discovery - getting to endgame. Curr Pharm Design 2002; 8(13): 1099-118.
159. Wiebe LI, Knaus E. E. Enzyme-targeted, nucleoside-based radiopharmaceuticals for scintigraphic monitoring of gene transfer and expression. Curr Pharm Design 2001; 7(18): 1893-906.